Lowering LDL in patients with heart disease: how aggressive should you be?

T. Pearson,F. Pashkow
DOI: https://doi.org/10.3949/CCJM.67.7.489
2000-07-01
Cleveland Clinic Journal of Medicine
Abstract:HE IMPORTANCE OF reducing low-density lipoprotein (LDL) cholesterol in managing patients with coronary heart disease ( C H D ) is unquestioned. However, debate continues over how aggressive physicians should be in lowering LDL. Experts have not been able to agree on a target level that is both beneficial and practical. In this month's Cardiology Dialogue, Dr. Thomas Pearson of the University of Rochester (NY) argues that lipid-lowering therapy should be individualized, not only on the basis of the LDL level but on other factors as well. Dr. Fredric Pashkow of the Cleveland Clinic, on the other hand, contends that aggressive therapy is warranted for all patients. Both discuss the merits and the failures of several recent high-profile studies and offer their personal insights on what constitutes rational therapy.
What problem does this paper attempt to address?